![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MARUHO AND SKYEPHARMA SIGN DEVELOPMENT AND MARKETING AGREEMENT FOR DEPOBUPIVACAINE IN JAPAN
MARUHO AND SKYEPHARMA SIGN DEVELOPMENT AND MARKETING AGREEMENT FOR DEPOBUPIVACAINE IN JAPAN
Maruho Company Limited ("Maruho") and SkyePharma PLC announce that
they have entered into a strategic agreement for the development, marketing
and distribution of DepoBupivacaine(TM) in Japan. DepoBupivacaine(TM) is SkyePharma's
novel sustained-release injectable formulation of the local anaesthetic bupivacaine
and is designed to provide localised pain relief for more than 48 hours after
a surgical operation.
PR
Newswire
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct